In the present study, we reviewed the demographic characteristics and clinical outcomes of patients with metastatic NSCLC who were referred to phase 1 trial center at The University of Texas MD Anderson Cancer Center in an effort to determine the impact of KRAS and TP53 mutations on their disease for the development of potential therapeutics. This evidence concerns the gene TP53 and non-small cell lung carcinoma.